In vitro and in vivo evaluation of a novel antiherpetic flavonoid, 4′-phenylflavone, and its synergistic actions with acyclovir

Archives of Virology

Volumn 157, Issue 8, 2012, Pages 1489-1498

  Hayashi, Kyoko ^a   Iinuma, Munekazu ^b   Sasaki, Kohei ^a   Hayashi, Toshimitsu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4' PHENYLFLAVONE; 4'-PHENYLFLAVONE; ACICLOVIR; FLAVONE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENITAL HERPES; HUMAN; MICROBIOLOGICAL EXAMINATION; MOUSE; PHYSIOLOGY; SIMPLEXVIRUS; VIROLOGY; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; CELL LINE; DRUG SYNERGISM; FEMALE; FLAVONES; HERPES GENITALIS; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SIMPLEXVIRUS; VIRUS INTERNALIZATION; VIRUS RELEASE; VIRUS REPLICATION;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS;

EID: 84864424839     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1335-6     Document Type: Article

References (31)

1. Arvin AM, Prober CG (1997) Herpes simplex virus type 2-a persistent problem. N Engl J Med 337: 1158-1159.
2. Badam L, Joshi SP, Bedekar SS (1999) 'In vitro' antiviral activity of neem (Azadirachta indica. A. Juss) leaf extract against group B coxsackieviruses. J Communicable Dis 31: 79-90.
3. Cohen MS (1998) Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351: 5-7.
4. Corey L, Handfield HH (2000) Genital herpes and public health: addressing a global problem. JAMA 283: 791-794.
5. Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208: 477-488.
6. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hyroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74: 5716-5720.
7. Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73: 7-13.
8. Furman PA, St Clair MH, Fyfe LA, Rideout JL, Keller PM, Elion GB (1979) Inhibitiion of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol 32: 72-77.
9. Griffiths PA (1996) Herpesviruses and AIDS. Scand J Infect Dis Suppl 100: 3-7.
10. Hayashi K, Hayashi T, Morita N (1992) Mechanism of action of the antiherpesvirus biflavone ginkgetin. Antimicrob Agents Chemother 36: 1890-1893.
11. Hayashi K, Hayashi T, Otsuka H, Takeda Y (1997) Antiviral activity of 5, 6, 7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. J Antimicrob Chemother 39: 821-824.
12. Hayashi K, Kawahara K, Nakai C, Sankawa U, Seto H, Hayashi T (2000) Evaluation of (1R, 2R)-1-(5′-methyfur-3′-yl)propane-1, 2, 3-triol, a sphydrofuran derivative isolated from a Streptomyces species, as an anti-herpesvirus drug. J Antimicrob Chemother 46: 181-189.
13. Hofmann WP, Soriano V, Zeuzem S (2009) Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handbook Exp Pharmacol 189: 321-346.
14. Honess RW, Roizman B (1974) Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 14: 8-19.
15. Honess RW, Watson DH (1977) Herpes simplex virus resistance and sensitivity to phosphonoacetic acid. J Virol 21: 584-600.
16. Jabs DA, Enger C, Dunn JP, Forman M (1998) Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 177: 770-773.
17. Jancel T, Penzak SR (2009) Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Seminars Hematol 46: 230-247.
18. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL (2003) Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 77: 4558-4565.
19. Keller MJ, Klotman ME, Herold BC (2003) Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 49: 279-284.
20. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L (1987) Recurrences after oral and genital herpes simplex virus infection. N Engl J Med 316: 1444-1449.
21. Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 72: 2760-2764.
22. Ljungman P (1996) Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 100: 59-63.
23. Miller WH, Miller RL (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 31: 3879-3884.
24. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A et al (1996) European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17: 813-817.
25. Robin V, Iruzun A, Amoros M, Boustie J, Carrasco L (2001) Antipoliovirus flavonoids from Psiadia dentata. Antiviral Chem Chemother 12: 283-291.
26. Sandoval IV, Carrasco L (1997) Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71: 4679-4693.
27. Serkedjieva J, Ivancheva S (1999) Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L. J Ethnopharmacol 64: 59-68.
28. Talarico LB, Castilla V, Ramirez JA, Galagovsky LR, Wachsman MB (2006) Synergistic in vitro interactions between (22S, 23S)-3β-bromo-5α, 22, 23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemother 52: 38-42.
29. Trager RS (2003) Microbicides: raising new barriers against HIV infection. Science 299: 39.
30. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seronegative persons: a meta-analysis. J Infect Dis 185: 45-52.
31. Wilson SS, Fakioglu E, Herold BC (2009) Novel approaches in fighting herpes simplex virus infections. Expert Rev Antiinfective Ther 7: 559-568.